Redemplo

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HypertriglyceridemiaFamilial Chylomicronemia Syndrome

17 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

1

Selzentry

GSK

Approved

—2

Crestor

AstraZeneca

Approved

—3

Lopid

Pfizer

Approved

—4

Cipro

Bayer

Approved

—5

Zocor

OOrganon and Co

Approved

—6

Topamax

WWim Janssens

Approved

—7

Tryngolza (autoinjector)

Ionis Pharmaceuticals

Phase 3

38

Redemplo

Arrowhead Pharmaceuticals

Phase 3

39

Avandia

Jazz Pharmaceuticals

Preclinical

110

Repatha

Amgen

Preclinical

1Show 5 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hypertriglyceridemia3 trials

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Available·Arrowhead Pharmaceuticals··NCT06796426

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

Recruiting·Arrowhead Pharmaceuticals·Phase 3·NCT06822790·869 enrolled

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

Active, not recruiting·Arrowhead Pharmaceuticals·Phase 3·NCT06347133·1,456 enrolled

Severe Hypertriglyceridemia3 trials

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

Recruiting·Arrowhead Pharmaceuticals·Phase 3·NCT06880770·288 enrolled

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

Active, not recruiting·Arrowhead Pharmaceuticals·Phase 3·NCT06347016·311 enrolled

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia

Active, not recruiting·Arrowhead Pharmaceuticals·Phase 3·NCT06347003·446 enrolled

Familial Chylomicronemia Syndrome2 trials

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting·Arrowhead Pharmaceuticals·Phase 3·NCT05089084·75 enrolled

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

Completed·VVisirna Therapeutics HK Limited·Phase 3·NCT05902598·37 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News